2312-7821

Safety and Risk of Pharmacotherapy

SCEEMP

View prefix report (10.30895)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 66 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact66 DOIs
2

Deposit reference lists for 55 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact55 DOIs
3

Attach ORCID iDs across 50 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact50 DOIs

DOIs for this ISSN

Showing the top 5 of 252 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Coronavirus disease COVID-2019 (10.30895/2312-7821-2020-8-1-3-8)
Abstract
43.70 55
2 Fluoroquinolone antibiotics: safety of use by the example of… (10.30895/2312-7821-2019-7-2-72-83)
Abstract
25.00 9
3 Gene Therapy Medicinal Products: Non-clinical Safety Studies (10.30895/2312-7821-2023-11-1-329)
Abstract
23.86 8
4 Safety of Remdesivir and Tocilizumab in COVID-19 Treatment (10.30895/2312-7821-2020-8-3-160-162)
ORCID
21.13 6
5 New Edition of the EAEU Good Pharmacovigilance Practice: Wha… (10.30895/2312-7821-2023-11-1-7-13)
Abstract
19.45 5
6 Pharmacogenetic Approaches to Enhancing Efficacy and Safety… (10.30895/2312-7821-2020-8-1-43-51)
Abstract
17.47 4
7 Analysis of Adverse Reactions in Elderly Patients Based on Q… (10.30895/2312-7821-2021-9-3-144-153)
Abstract
17.47 4
8 Genetic features of a patient may influence the efficacy and… (10.30895/2312-7821-2024-12-2-127-131)
References
17.47 4
9 Drug Safety for Children — International Monitoring Data fo… (10.30895/2312-7821-2019-7-2-57-64)
Abstract
15.05 3
10 Drug-Induced Eosinophilia (10.30895/2312-7821-2019-7-4-176-189)
Abstract
15.05 3
11 Monitoring Drug Safety Information - Recommendations of Fore… (10.30895/2312-7821-2020-8-1-52-54)
References ORCID
15.05 1
12 Drug Safety Monitoring Information (10.30895/2312-7821-2020-8-2-104-106)
References ORCID
15.05 1
13 PCSK9 Monoclonal Antibodies for the Primary and Secondary Pr… (10.30895/2312-7821-2023-11-4-473-474)
References ORCID
15.05 1
14 Quantitative Signal Detection for COVID-19 Medicinal Product… (10.30895/2312-7821-2023-382)
Abstract
15.05 3
15 Some Aspects of Drug Induced Nephrotoxicity Assessment (10.30895/2312-7821-2020-8-3-123-133)
Abstract
11.93 2
16 Preparation for the Inspection of the Pharmacovigilance Syst… (10.30895/2312-7821-2021-9-3-111-116)
Abstract
11.93 2
17 Comparative Analysis of Drug Interactions with Antibacterial… (10.30895/2312-7821-2021-9-3-136-143)
Abstract
11.93 2
18 Organisation of the Russian Pharmacovigilance System: Survey… (10.30895/2312-7821-2021-9-3-154-160)
Abstract
11.93 2
19 Risk Management Plan: An Expert Analysis of Changes to the E… (10.30895/2312-7821-2023-11-1-30-37)
Abstract
11.93 2
20 Off-Label Prescribing in Paediatric Cardiology: Regulatory A… (10.30895/2312-7821-2023-11-1-52-62)
Abstract
11.93 2
21 Conducting Pharmaceutical Inspections in the Russian Federat… (10.30895/2312-7821-2023-11-2-127-130)
References
11.93 2
22 Complications of Pharmacotherapy with New Oral Anticoagulant… (10.30895/2312-7821-2019-7-2-65-71)
Abstract
7.53 1
23 Interferon Beta: Analysis of Information on Adverse Reaction… (10.30895/2312-7821-2019-7-2-84-92)
Abstract
7.53 1
24 Analysis of Safety Issues of Using Statins in Patients with… (10.30895/2312-7821-2019-7-4-163-175)
Abstract
7.53 1
25 Ongoing challenges and future directions of human papillomav… (10.30895/2312-7821-2020-8-3-141-150)
Abstract
7.53 1
26 Drug Safety Monitoring—International Information (10.30895/2312-7821-2020-8-4-211-213)
References
7.53 1
27 Drug Safety Monitoring Information (10.30895/2312-7821-2021-9-2-103-105)
References
7.53 1
28 Periodic Benefit–Risk Evaluation Report: A Review of Changes (10.30895/2312-7821-2023-11-1-46-51)
Abstract
7.53 1
29 Transition to the Non-Clinical Drug Development Principles a… (10.30895/2312-7821-2023-11-3-246-251)
References
7.53 1
30 Post-marketing pharmacovigilance methods: Spontaneous report… (10.30895/10.30895/2312-7821-2026-14-2-184-194)
0.00 0
31 Editorial (10.30895/2312-7821-2018-6-4-149)
References ORCID
0.00 0
32 Assessment of Pharmacovigilance Reporting in Russia (10.30895/2312-7821-2018-6-4-150-154)
0.00 1
33 Revisiting the Safety of Vaccination against the Flu in Elde… (10.30895/2312-7821-2018-6-4-155-161)
0.00 2
34 Adverse Reactions of Drugs Containing Valeriana and Corvalol… (10.30895/2312-7821-2018-6-4-162-173)
0.00 1
35 Non-pharmacological Approaches to Treatment of Patients over… (10.30895/2312-7821-2018-6-4-174-179)
0.00 1
36 Signal Messages in Pediatric Practice (10.30895/2312-7821-2018-6-4-180-186)
0.00 1
37 The Case of Сushing Syndrome in a Child of 15 Years after Pr… (10.30895/2312-7821-2018-6-4-187-190)
0.00 2
38 The Adverse Drug Reactions Registered During the Postmarketi… (10.30895/2312-7821-2019-7-1-15-22)
0.00 4
39 Malnutrition in Elderly Patients as a Complication of a Drug… (10.30895/2312-7821-2019-7-1-23-30)
0.00 0
40 Literature Monitoring for Pharmacovigilance (10.30895/2312-7821-2019-7-1-31-43)
0.00 1
41 Learning Needs as a Reflection of Professional Interests amo… (10.30895/2312-7821-2019-7-1-44-52)
0.00 1
42 Vaccine Safety International Monitoring (10.30895/2312-7821-2019-7-1-6-14)
0.00 3
43 Safety of Use of Russian Biosimilars of Interferon Beta-1b i… (10.30895/2312-7821-2019-7-2-93-98)
Abstract
0.00 0
44 Analysis of the decisions of foreign regulatory authorities (10.30895/2312-7821-2019-7-2-99-104)
Abstract References ORCID
0.00 0
45 Topical Issues of Drug Safety, Possibilities of Improving of… (10.30895/2312-7821-2019-7-3-109-119)
0.00 22
46 International Drug Safety Monitoring (10.30895/2312-7821-2019-7-3-120-126)
0.00 5
47 Nanoscale Therapeutic System: Safety Assessment Features (10.30895/2312-7821-2019-7-3-127-138)
0.00 6
48 Opioids and Migraine: Opioid Awareness and Frequency of Use… (10.30895/2312-7821-2019-7-3-139-145)
0.00 0
49 A Case of Multiple Antibiotic-Associated Hepatotoxicity in a… (10.30895/2312-7821-2019-7-3-146-151)
0.00 2
50 Analysis of Administrative Decisions of Foreign Regulatory A… (10.30895/2312-7821-2019-7-3-152-158)
References ORCID
0.00 0